REZLIDHIA

Indicated For

relapsed or refractory acute myeloid leukemia (AML) with susceptible IDH1 mutation

About This Medication

# Rigel OneCare Patient Assistance Program Patient Guide: How to Get REZLIDHIA (olutasidenib) at Low or No Cost REZLIDHIA (olutasidenib) is a targeted oral capsule medication approved for adults with relapsed or refractory acute myeloid leukemia (AML) harboring an isocitrate dehydrogenase-1 (IDH1) mutation, as confirmed by an FDA-approved test. The **Rigel OneCare Patient Assistance Program (PAP)** from Rigel Pharmaceuticals helps eligible uninsured or underinsured patients aged 18+ access REZLIDHIA at no cost if they meet income guidelines and other criteria. ## About REZLIDHIA (olutasidenib) REZLIDHIA is a once-daily oral therapy that works by blocking the mutated IDH1 enzyme, which can help restore normal blood cell production in certain AML patients. It's specifically for adults whose AML has not responded to or has returned after prior treatments. Common side effects include fatigue, constipation, joint pain, and nausea—always discuss with your doctor. Treatment is typically ongoing, with regular blood tests to monitor response and safety. This guide focuses on financial support; consult your healthcare provider for medical advice.[1][9] ## Who Qualifies for the Program? The Rigel OneCare PAP is designed for patients facing financial barriers. Key eligibility includes: - **Age**: 18 years or older. - **Residency**: U.S. resident or U.S. territory (including Puerto Rico). - **Indication**: On-label use only (relapsed/refractory AML with IDH1 mutation). - **Insurance**: Uninsured or underinsured (government programs like Medicare/Medicaid do not qualify for copay assistance, but PAP may apply for uninsured).[1][3][5] - **Income**: Household income at or below **500% of the Federal Poverty Level (FPL)**. - **Treatment Setting**: Outpatient basis with a licensed U.S. healthcare provider. Rigel OneCare evaluates all applications and matches patients to the best program, which may include free drug supply or copay help for commercially insured.[1][5] ## Income Eligibility Breakdown Eligibility is based on household size and income relative to the **2026 Federal Poverty Level (FPL)** guidelines. The program covers up to **500% FPL**. Use the table below to check—proof like tax returns or pay stubs is often required. | Household Size | Annual Income Limit (500% FPL) | |----------------|--------------------------------| | 1 (Individual) | $75,300 | | 2 (Couple) | $102,000 | | 3 | $128,600 | | 4 | $155,300 | | 5 | $181,900 | | Add per person | +$26,600 | *Notes: FPL updated annually; confirm current levels at healthcare.gov. Income includes all household sources. Alaska/Hawaii have higher thresholds.*[3] ## Insurance Requirements - **Uninsured**: Fully eligible for PAP free drug if other criteria met. - **Underinsured**: May qualify for PAP or bridge supply during coverage delays. - **Commercially Insured**: Not for PAP; instead, copay assistance reduces costs to $0-$15 per fill (up to $25,000 annual cap). Medicare, Medicaid, or government insurance ineligible for copay programs.[1][5] Rigel OneCare's team verifies benefits and appeals denials.[2] ## Step-by-Step Application Process 1. **Discuss with Your Doctor**: Confirm REZLIDHIA prescription and IDH1 mutation status. Your healthcare provider (HCP) must complete part of the form. 2. **Contact Rigel OneCare**: Call **(833) 744-3562** (Mon-Fri, 8am-8pm ET) for guidance. They assess which program fits (PAP, copay, or free supply).[1][2] 3. **Download/Request Form**: Get the enrollment form from rezlidhia.com or rigelonecare.com. It's a combined form for all Rigel programs.[1][3] 4. **Complete the Form**: Patient provides personal info, income proof, insurance details (copy both sides of cards). HCP signs prescription and eligibility sections. 5. **Submit**: Fax to (833) 397-4435 or as instructed. Multiple methods available.[3] 6. **Follow Up**: Program team reviews and contacts you. Approval leads to shipment.[1] **Required Documents**: - Completed enrollment form (patient + HCP signatures). - Proof of income (e.g., last 3 pay stubs, tax return). - Insurance cards (if applicable). - Prescription.[1][3] ## Timeline and Delivery Processing time varies but expect 5-10 business days for review. For urgent needs (insurance delays >5 days), temporary free supply up to 60 days is available quickly. Approved PAP medication ships free to your home or doctor's office. Reauthorization is required periodically—your doctor resubmits updates.[1][5][8] ## Alternatives if Denied or Ineligible - **Copay Program**: If commercially insured, enroll at REZLIDHIAcopay.com for $0-$15 per fill.[2][5] - **Free Drug Bridge**: Up to 60 days during appeals.[8] - **Other Resources**: Check rxassist.org, NeedyMeds, or PAN Foundation. State programs or generic alternatives (none currently for olutasidenib). Appeal denials via Rigel OneCare.[6] - **Financial Counseling**: Hospitals or nonprofits like CancerCare offer grants. ## Important Disclaimer This guide is for informational purposes only and based on publicly available program details as of 2026. Programs can change; always verify with Rigel OneCare at (833) 744-3562 or official sites. Not medical advice—consult your doctor. Rigel Pharmaceuticals reserves rights to modify eligibility. Patients assume responsibility for application accuracy.

Program information last verified: March 30, 2026